Microparticles in tumor progression
References (62)
Cell-derived microparticles: “Miniature envoys with many faces”
J Thromb Haemost
(2005)- et al.
Differential stimulation of monocytic cells results in distinct populations of microparticles
J Thromb Haemost
(2009) - et al.
Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles
Blood
(2009) - et al.
Impact of pre-analytical parameters on the measurement of circulating microparticles: towards standardization of protocol
J Thromb Haemost
(2012) - et al.
Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus
Atherosclerosis
(1995) - et al.
Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists
J Thromb Haemost
(2004) - et al.
Cellular origin and procoagulant properties of microparticles in meningococcal sepsis
Blood
(2000) - et al.
Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism
J Am Coll Cardiol
(2005) - et al.
Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner
J Thromb Haemost
(2003) - et al.
Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation
Trends Mol Med
(2004)
Procoagulant mechanisms in tumour cells
Best Pract Res Clin Haematol
Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor
Eur J Cancer
Microvesicle-associated tissue factor and Trousseau's syndrome
J Thromb Haemost
Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients
Thromb Res
Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis
Blood
Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells
Blood
Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation
J Thromb Haemost
Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism
Thromb Res
Monocyte-derived microparticles may be a sign of vascular complication in patients with lung cancer
Lung Cancer
Microparticle-associated tissue factor activity: a link between cancer and thrombosis?
J Thromb Haemost
Microparticle-associated tissue factor activity in cancer patients with and without thrombosis
J Thromb Haemost
Predictive value of tissue factor bearing microparticles in cancer associated thrombosis
Thromb Res
Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer
J Thromb Haemost
Procoagulant myeloblast-derived microparticles in AML patients: changes in numbers and thrombin generation potential during chemotherapy
J Thromb Haemost
Cancer and venous thromboembolism
Lancet Oncol
Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures
Blood
Tissue factor in cancer progression and angiogenesis
Thromb Res
Suppression of membrane microvesiculation – a possible anticoagulant and anti-tumor progression effect of heparin
Blood Cells Mol Dis
Microparticles in cardiovascular diseases
Cardiovasc Res
Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy
Clin Cancer Res
Measuring circulating cell-derived microparticles
J Thromb Haemost
Cited by (54)
Hemostatic system activation in breast cancer: Searching for new biomarkers for cancer risk prediction and outcomes
2022, Thrombosis ResearchCitation Excerpt :TF expressed by breast cancer cells can efficiently activate TG in vitro [25,26], but can also be responsible for the increased VEGF expression [27] and microparticle (MPs) shedding from the same breast cancer cells [28]. MPs are important actors in angiogenesis and hypercoagulability, being plentiful in proangiogenic and prothrombotic factors [29], and in cancer, MPs can be of both tumor and vascular cell (i.e., platelets, leukocytes, erythrocytes, endothelial cells) origins [30,31]. Increased MPs procoagulant activity are found in breast cancer patients after adjuvant and neoadjuvant chemotherapy [32].
Hemostatic biomarkers in cancer progression
2018, Thrombosis ResearchCitation Excerpt :Tumor TF expression was an independent prognostic indicator for OS in breast cancer [65] and for DFS in osteosarcoma [66]. Under pathological conditions, TF can be detected at increased concentration in plasma where it circulates alone or associated to cellular derived microparticles (MP) expressing also the procoagulant phosphatidylserine (PS) [67, 68]. TF-containing MP is the main source of TF activity released from human cancer cells [69].
Platelet populations and priming in hematological diseases
2017, Blood ReviewsMechanisms and risk factors of thrombosis in cancer
2017, Critical Reviews in Oncology/HematologyCitation Excerpt :These small membrane vesicles carry high concentrations of procoagulant phosphatidylserine and TF (Falanga et al., 2012). The pathogenetic role of MPs in cancer-associated thrombosis is demonstrated by the development of a DIC-like syndrome in mice after intravenous injection of highly TF-positive MPs of tumor origin (Falanga et al., 2012). Elevated levels of circulating MPs have been described in cancer patients, with both solid and hematologic malignancies and play a role in the establishment of the hypercoagulable state (Falanga and Marchetti, 2009; Tilley et al., 2008; Del Conde et al., 2007; Kim et al., 2003).
miRNA and long non-coding RNA transcriptional expression in hepatocellular carcinoma cell line-secreted extracellular vesicles
2022, Clinical and Experimental Medicine